Please wait while the formulary information is being retrieved.
PROLASTIN C (ALPHA-1-PROTEINASE INHIBITOR)
- Alpha-1-proteinase inhibitor deficiency emphysema
- Zemaira Iv Susp
- Zemaira Intravenous Solution
- Prolastin-c Intravenous Solution
- Prolastin-c Intravenous Powder For Solution
- Prolastin C Iv Susp
- Aralast Np Iv Susp
- Aralast Np Intravenous Solution
- By Indication
1,000 mg intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
1,000 mg intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
Prolastin-C 1,000 mg (+/-)/20 mL intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
Prolastin-C 1,000 mg intravenous powder for solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
Prolastin-C 1,000 mg intravenous powder for solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
1,000 mg intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
500 mg intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
1,000 mg intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
500 mg intravenous solution
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
Alpha-1-proteinase inhibitor deficiency emphysema
- Infuse 60 mg/kg by intravenous route once weekly
- Infuse 60 mg/kg at a rate not to exceed 0.2 ml/kg/min by intravenous route once weekly
- Infuse 60 mg/kg at a rate of 0.08 ml/kg/min by intravenous route onceweekly
- None
Contraindicated
- None
Severe
Moderate
- None
- IgA deficiency
Contraindicated
- None
Severe
Moderate
- Hypervolemia
PROLASTIN C (ALPHA-1-PROTEINASE INHIBITOR)
- Alpha-1-proteinase inhibitor deficiency emphysema
- None
- Headache disorder
- Myalgias
More Frequent
Severe
Less Severe
- None
- Injection site sequelae
- Pharyngitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Asthma
Less Severe
- Abdominal distension
- Back pain
- Bronchitis
- Chest pain
- Chills
- Conjunctivitis
- Diarrhea
- Dizziness
- Drowsy
- Dysmenorrhea
- Dyspnea
- Fatigue
- Fever
- Flushing
- General weakness
- Hypertonia
- Hypesthesia
- Insomnia
- Leukocytosis
- Malaise
- Nausea
- Nervousness
- Peripheral edema
- Pruritus of skin
- Rhinorrhea
- Skin rash
- Tinnitus
- Urticaria
- Vasodilation of blood vessels
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Alpha 1-Proteinase Inhibitor
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Alpha(sub 1) Proteinase Inhibitor
- Severity Level:
C
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Alpha-1-proteinase Inhibitor
Caution should be exercised
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Caution should be exercised |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Alpha-1-proteinase inhibitor deficiency emphysema | |
| E88.01 | Alpha-1-antitrypsin deficiency |
| 0-9 | A-Z |
|---|---|
| E88.01 | Alpha-1-antitrypsin deficiency |
Formulary Reference Tool